2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2004
October 14, 2004
Aegera establishes a clinical advisory board
March 29, 2004
Aegera initiates phase 1 oncology clinical trial of XIAP antisense designed to stimulate apoptotic cell death in cancer cells
February 24, 2004
Aegera Therapeutics announces $20 million Series B financing round
January 30, 2004
AEG35156 exhibits significant antitumor activity alone and in combination with chemotherapeutics in preclinical human cancer xenograft models
About Aegera
|
Pipeline
|
Clinical Trials
|
Partnerships
|
Media
|
Careers
|
Contact Us
|
Français
© 2010 Aegera Therapeutics Inc. All rights reserved. Developed by
Grafika Designs
.
